|
Two sequential dose-dense regimens of CGP, followed by MVAC in patients with metastatic urothelial carcinoma (mUC): A single institution, explorative trial. |
| |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi |
| |
|
Consulting or Advisory Role - Roche |
Speakers' Bureau - AstraZeneca |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |